RecruitingNCT05522881

The Registry Study of Genetic Alterations of Oropharyngeal Cancer in Taiwan

Sponsor

National Health Research Institutes, Taiwan

Enrollment

410 participants

Start Date

Nov 25, 2022

Study Type

OBSERVATIONAL

Conditions

Oropharyngeal Squamous Cell Carcinoma

Summary

We will use the next-generation sequencing (NGS) technology to identify genomic alterations of Taiwanese HPV positive and negative oropharyngeal squamous cell carcinoma (OPSCC) for novel biomarker development and the study design of potential clinical trials or translational research.

Eligibility

Min Age: 20 Years

Inclusion Criteria8

Ages 20 and above
Pathological reported as squamous cell carcinoma of head and neck
Available p16 immunohistochemical staining status (restricted to the OPSCC subgroup)
Participants have both archival tumor tissues from the primary head and neck SCC and from the first recurrent tumor (for the recurrence subgroup)
Recurrence status is defined as the reappearance of the disease occurring more than 6 months following curative surgery and/or chemoradiotherapy in the recurrence subgroup
Willingness to provide archival or newly obtained tumor tissues for current study proposal
Life expectancy more than 3 months
Patients fully understand the protocol with the willingness to have regular follow-up

Exclusion Criteria4

Inability to cooperate by providing a complete medical history
No available tumor tissues for genetic testing
Undesirable compliance
Having a known additional malignancy that is progressing or has required active treatment within the past 3 years. Participants with basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or carcinoma in situ (e.g., cervical carcinoma in situ) that have undergone potentially curative therapy are not excluded